^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    IL4I1 (Interleukin 4 Induced 1)

    i
    Other names: IL4I1, Interleukin 4 Induced 1, FIG1, L-Amino-Acid Oxidase, IL4-Induced Protein 1, HIL4I1, LAAO, LAO, Interleukin-4-Induced Protein 1, Interleukin Four Induced 1, Fig-1 Protein, Protein Fig-1, HFIG1
    Associations

    News

    Trials
    7d
    Fatty acid metabolism-related signature suggests an oncogenic role of FASN in cervical cancer. (PubMed, Transl Cancer Res)
    This study clarified a specific signature associated with fatty acid metabolism, specifically FASN, which is connected to both the initiation and progression of CESC. Furthermore, FASN may serve as a prognostic marker for individuals diagnosed with CESC, thus providing fresh insights for the formulation of clinical treatment strategies.
    Journal
    |
    FAS (Fas cell surface death receptor) • FASN (Fatty acid synthase) • HMGCS1 (3-Hydroxy-3-Methylglutaryl-CoA Synthase 1) • IL4I1 (Interleukin 4 Induced 1) • TP53INP2 (Tumor Protein P53 Inducible Nuclear Protein 2)
    21d
    Prognostic and immunological significance of tryptophan metabolic enzymes across endometrial cancer molecular subtypes. (PubMed, Gynecol Oncol)
    Tryptophan-kynurenine enzymes shape the immune landscape of EC in a subtype-specific manner. High IDO1 was linked to favourable outcomes in p53mut and NSMP cases, whereas TDO2 predicted poor prognosis. The CD163:CD8 ratio emerged as an independent marker of poor survival. These findings support therapeutic strategies combining dual IDO1/TDO2 inhibition or targeting the IL4I1- aryl hydrocarbon receptor (AhR) axis to enhance immunotherapy efficacy in EC.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • TP53 (Tumor protein P53) • CD8 (cluster of differentiation 8) • CD163 (CD163 Molecule) • IDO1 (Indoleamine 2,3-dioxygenase 1) • CD68 (CD68 Molecule) • FOXP3 (Forkhead Box P3) • TDO2 (Tryptophan 2,3-Dioxygenase) • IL4I1 (Interleukin 4 Induced 1)
    |
    TP53 mutation • MSI-H/dMMR
    2ms
    Intraepithelial Lymphocytes and LAIR1 Expression in Celiac Disease. (PubMed, Biomedicines)
    IELs exhibit a cytotoxic T-cell phenotype and were found to be CD3+, CD8+, CD103+, TCR beta+, and LAIR1+ in the small intestine control. Increased numbers of LAIR1+ IELs and lamina propria immune cells characterize CD.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • CD163 (CD163 Molecule) • CD4 (CD4 Molecule) • NCAM1 (Neural cell adhesion molecule 1) • TNFRSF14 (TNF Receptor Superfamily Member 14) • GZMB (Granzyme B) • BTLA (B And T Lymphocyte Associated) • FCGR3A (Fc Fragment Of IgG Receptor IIIa) • FOXP3 (Forkhead Box P3) • ITGAE (Integrin Subunit Alpha E) • IL4I1 (Interleukin 4 Induced 1) • LAIR1 (Leukocyte Associated Immunoglobulin Like Receptor 1) • CD3E (CD3 Epsilon Subunit Of T-Cell Receptor Complex)
    3ms
    Proteomic Identification of IL4I1 as a Therapeutic Target in P53-Mutant Endometrial Cancer. (PubMed, Cancers (Basel))
    IL4I1 is a key player in the aggressiveness of P53-mutant EC. It holds promise as a prognostic biomarker and may serve as a novel target for precision therapies in this high-risk EC subtype.
    Journal • P53mut
    |
    TP53 (Tumor protein P53) • IL4I1 (Interleukin 4 Induced 1)
    |
    TP53 mutation
    6ms
    Tryptophan Metabolite Indole-3-Aldehyde Induces AhR and c-MYC Degradation to Promote Tumor Immunogenicity. (PubMed, Adv Sci (Weinh))
    Moreover, overexpression of the Trp metabolic enzyme interleukin-4-induced gene-1 (IL4I1) in tumor cells increases the intracellular level of I3A and enhances tumor immunogenicity. In summary, I3A is identified as a tumor immunogenicity inducer, which holds the potential to enhance antitumor immunotherapy efficacy.
    Journal • IO biomarker
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • IL4 (Interleukin 4) • IL4I1 (Interleukin 4 Induced 1)
    7ms
    Identification of potential IL4I1 inhibitors through structure-based virtual screening and molecular dynamics simulations. (PubMed, J Biomol Struct Dyn)
    After further MD simulation and following Molecular Mechanics/Generalized Born Surface Area (MM/GBSA) calculation of binding free energy and ADMET analysis, five candidate IL4I1 inhibitors were obtained. This study provides an effective in silico approach for the identification of IL4I1 inhibitors and offers a valuable reference for the virtual screening of inhibitors targeting other proteins without known structures.
    Journal
    |
    IL4 (Interleukin 4) • IL4I1 (Interleukin 4 Induced 1)
    7ms
    Metabolic reprogramming and immune microenvironment profiling in clear cell renal cell carcinoma: implications for prognosis, targeted therapy, and drug resistance. (PubMed, Discov Oncol)
    Drug sensitivity analysis suggested that AKT inhibitor III was more effective in the low-risk cohort, while Bortezomib might be more beneficial for high-risk patients...Methylation profiling of the core genes via the UALCAN platform revealed distinct epigenetic signatures in ccRCC, providing deeper insight into the disease's molecular mechanisms. This study contributes to a more comprehensive understanding of ccRCC and proposes valuable directions for personalized treatment strategies and enhanced patient management.
    Journal • Tumor mutational burden
    |
    TMB (Tumor Mutational Burden) • PBRM1 (Polybromo 1) • BCAT1 (Branched Chain Amino Acid Transaminase 1 ) • IL4I1 (Interleukin 4 Induced 1) • ACADM (Acyl-CoA Dehydrogenase Medium Chain) • ACADSB (Acyl-CoA Dehydrogenase Short/Branched Chain)
    |
    TMB-H • VHL mutation
    |
    bortezomib
    7ms
    IL4I1 knockdown inhibits the epithelial-mesenchymal transition process in glioma via downregulation of the JAK2/STAT3 signaling pathway. (PubMed, Neoplasma)
    The results of in vivo experiments confirmed that IL4I1 knockdown effectively suppressed glioma growth. Our research demonstrates that IL4I1 knockdown reverses the EMT process via JAK2/STAT3 signaling pathway and suppresses the malignant phenotypes of glioma, thereby highlighting its potential as both a prognostic marker and therapeutic target for glioma.
    Journal
    |
    IL4 (Interleukin 4) • IL4I1 (Interleukin 4 Induced 1)
    8ms
    Immunohistochemical Profiling of IDO1 and IL4I1 in Head and Neck Squamous Cell Carcinoma: Interplay for Metabolic Reprogramming? (PubMed, Int J Mol Sci)
    A low IL4I1 expression in HNSCC led to a significantly better OS in this study, while IDO1 expression did not have a significant effect. Additional studies are necessary to investigate the complex interplay in the metabolic reprogramming of tumor cells.
    Journal • IO biomarker
    |
    IDO1 (Indoleamine 2,3-dioxygenase 1) • IL4I1 (Interleukin 4 Induced 1)
    9ms
    Monocyte-lineage tumor infiltration predicts immunoradiotherapy response in advanced pretreated soft-tissue sarcoma: phase 2 trial results. (PubMed, Signal Transduct Target Ther)
    Here, we report the results of the STS cohort of the SABR-PDL1 phase II trial that evaluated the anti-PDL1 atezolizumab combined with stereotactic body radiation therapy (SBRT) delivered concurrently with the 2nd cycle to at least one tumor site...EudraCT No. 2015-005464-42; Clinicaltrial.gov number: NCT02992912.
    P2 data • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    HES1 (Hes Family BHLH Transcription Factor 1) • IL4I1 (Interleukin 4 Induced 1)
    |
    Tecentriq (atezolizumab)
    9ms
    Spatial Metabolomics and Transcriptomics Reveal Metabolic Reprogramming and Cellular Interactions in Nasopharyngeal Carcinoma with High PD-1 Expression and Therapeutic Response. (PubMed, Theranostics)
    Immunohistochemical analysis further confirmed that high expression of these six genes was significantly associated with poor prognosis in NPC patients, a trend corroborated by data from the TCGA head and neck cancer cohort. This study highlights the pivotal roles of key molecular players in therapeutic response in NPC, providing compelling evidence for their potential application as prognostic biomarkers and therapeutic targets, thereby contributing to precision oncology strategies aimed at improving patient outcomes.
    Journal • PD(L)-1 Biomarker • IO biomarker • Metabolomic study
    |
    OXCT1 (3-Oxoacid CoA-Transferase 1) • IL4I1 (Interleukin 4 Induced 1)
    9ms
    Tryptophan Metabolic Enzyme IL4I1 Inhibits Ferroptosis by Decreasing Ubiquitination of Nrf2 via I3P in Glioblastoma. (PubMed, Cell Prolif)
    In vivo, overexpression of IL4I1 with ML385 in GBM xenografts promoted ferroptosis. Collectively, this study emphasises the crucial roles of IL4I1 in anti-ferroptosis through Nrf2 signalling pathway but not AHR pathway by catabolism tryptophan, suggesting IL4I1 and tryptophan reprogramming as potential therapeutic targets for GBM.
    Journal
    |
    IL4 (Interleukin 4) • IL4I1 (Interleukin 4 Induced 1)